Short answer
Organogenesis Holdings Inc. (ORGO) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $151M (up 31.0% year over year) with net income of $22M.
Q3 2025 key financials · XBRL
- Revenue
- $151M
- +31.0% YoY · +49.4% QoQ
- Net income
- $22M
- +74.9% YoY · +329.6% QoQ
- Operating margin
- 13.7%
- EPS (diluted)
- $0.15
- +66.7% YoY · +250.0% QoQ
Source: XBRL data from the Organogenesis Holdings Inc. (ORGO) Q3 2025 10-Q on SEC EDGAR. USD.
Organogenesis Holdings Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $150.9M vs $115.2M YoY, up $35.7M
- Advanced Wound Care $141.5M, up 31%; Surgical & Sports Medicine $9.0M, up 25%
- Gross margin 75.7% vs 76.7% YoY; operating margin 13.7% vs 5.4%
- Adjusted EBITDA $30.1M vs $13.4M YoY
- LCD implementation delays and proposed 2026 CMS payment changes pose utilization, revenue, and profitability headwinds
Risk Factors
- Medicare coverage risk: Seven MAC LCDs delayed to January 1, 2026, potentially classifying more than 200 products as non-covered
- ReNu regulatory risk: Second Phase 3 RCT missed statistical significance, creating uncertainty around FDA acceptance and BLA approval
- Medicare reimbursement risk: CMS finalized approximately $127.28-per-square-centimeter 2026 PFS payment for certain skin substitutes
- Liquidity risk: Revolving Facility reduced from $125 million to $75 million under October 2025 credit amendment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Organogenesis Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.